Caris Life Sciences Launches Commercial Caris Detect Test Using AI and 50 Billion Markers
CAI•Caris Life Sciences has launched Caris Detect, a blood-based multi-cancer early detection test using ultra-deep genome and transcriptome sequencing with AI to analyze DNA and RNA signals. Backed by over one million cases and 50 billion molecular markers, it aims to identify cancers at earlier, more treatable stages.
1. Commercial Launch of Caris Detect
On July 1, 2026, Caris Life Sciences began commercial sales of Caris Detect, its blood-based multi-cancer early detection test. The test combines ultra-deep whole genome and transcriptome sequencing with artificial intelligence to screen for cancer signals from DNA and RNA.
2. Advanced Sequencing and AI Platform
Caris Detect leverages Caris’ molecular profiling database of more than one million cases and 50 billion molecular markers. Its AI algorithms analyze a broad spectrum of genomic and biological signals to enhance detection sensitivity beyond current screening methods.
3. ACHIEVE 1 Study Validation
Initial results from the ACHIEVE 1 study demonstrated strong performance in detecting early-stage cancer signals across multiple tumor types. These findings support Caris Detect’s potential to serve as a new standard of care for earlier intervention.
4. Market Potential and Future Outlook
Caris aims to drive diagnostic revenue growth as the test enters clinical use and pursues payer coverage. Ongoing research and upcoming study milestones will expand clinical evidence and broaden applications across additional cancer indications.
